Summary
The neuroendocrine effects (changes in plasma CRF, ACTH and cortisol) of single and multiple (t.d.s. for 2 days) doses of ipsapirone (BAY Q 7821) 5 and 10 mg have been investigated in 6 healthy male volunteers. The study followed a balanced complete block, placebo-controlled and double blind design with two baseline phases (pre and post-treatment). Volunteers were investigated on identical days during 5 successive weeks.
The results do not show a specific effect of ipsapirone on the hypothalamic-pituitary-adrenal axis when doses in the range of 5–30 mg per day were given.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson IM, Cowen PJ, Grahame-Smith DG (1990) The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacol 100: 498–503
Andrade R, Nicoll RA (1987) Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 336: 5–10
Beneke M, Kümmel B, Roed IS, Spechtmeyer H (1988) Treatment of anxiety neurosis with ipsapirone. Psychopharmacol 96 (Suppl) 353: # 33.03.13
Box GEP, Tiao GC (1975) Intervention analysis with applications to economic and environmental problems. JASA 349: 70–79
Box GEP, Jenkins GM (1976) Time series analysis: forecasting and control, Holden-Day, San Francisco
Campbell DT, Stanley JC (1966) Experimental and quasi-experimental designs for research. Chicago, Rand McNally
Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 8: 383–388
Cowen PJ (1987) Psychotropic drugs and human 5-HT neuroendocrinology. Trends Pharmacol Sci 8: 105–108
Dahme B, Koch U, Poeppel E (1986) Psychologie in der Medizin. VCH, Weinheim
De Vry J, Glaser T, Traber J (1990a) 5-HT1A receptor partial agonists as anxiolytics. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds) Serotonin, from Cell Biology to Pharmacology and Therapeutics. Kluwer, Dordrecht, pp 517–522
De Vry J, Glaser T, Schuurmann T, Schreiber R, Traber J (1990b) 5-HT1A Receptors in Anxiety. In: Briley M, File SE (eds) New concepts in anxiety. MacMillan Press, London, pp 94–129
Frohman L, Stachura ME (1975) Neuropharmacologic control of neuroendocrine function in man. Metabolism 24: 211–234
Gilbert F, Brazell C, Tricklebank MD, Stahl SM (1988) Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol 147: 431–439
Glaser T, Raht M, Traber J, Zilles K, Schleicher A (1985) Autoradiographic identification and topographical analyses of high affinity serotonin receptor subtypes as a target for the putative anxiolytic TVX Q 7821. Brain Res 358: 129–136
Glass GV, Wilson VL, Gottman JM (1975) Design and analysis of time-series experiments. Colorado Association University Press
Gottman J, Markman HJ (1978) Experimental designs in psychotherapy research. In: Garefield SL, Bergin AE (eds) Handbook of psychotherapy and behavior change: An empirical analysis, 2nd ed Wiley and Sons, New York, pp 23–62
Gray JA (1982) The neuropsychology of anxiety. OUP, Oxford
Hjorth S, Carlsson A, Magnusson T, Arvidson LE (1987) In vivo biochemical characterization of 8-OH-DPAT—evidence for 5-HT receptor selectivity and agonist action in the rat CNS. In: Dourish CT, Ahlenius S, Hutson PH (eds) Brain 5-HT1A receptors: biochemical and neurochemical pharmacology, Ellis Horwood, Chichester, pp 94–105
Jones MT, Hillhouse EW, Burden J (1976) Effect of various putative neurotransmitters on the secretion of eorticotrophin-releasing hormone from the rat hypothalamus in vitro — A model of the neurotransmitters involved. Endocrinol 69: 1–10
Kazdin AE (1982) Single-case research designs. Methods for clinical and applied settings. OUP, New York, Oxford
Keller-Wood ME, Dallman MF (1984) Corticosteroid inhibition of ACTH secretion. Endocrine Rev 5: 1–24
König JI, Meltzer HY, Gudelsky GA (1988) 5-hydroxy-tryptamine-1A receptor-mediated effects of buspirone, gepirone and ipsapirone. Pharmacol Biochem Behavior 29: 711–715
Kümmel B, Beneke M, Krol G, Schöllnhammer G, Spechtmeyer H (1988) Ipsapirone in the treatment of generalized anxiety disorders. Results of a phase II US-multicenter trial. Psychopharmacol 96 [Suppl]: 353, # 33.03.12
Lesch K-P, Rupprecht R, Poten B, Müller U, Söhnle K, Fritze J, Schulte HM (1989) Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiat 26: 203–205
Liposits ZS, Phelix C, Paull WK (1987) Synaptic interactions of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Histochem 86: 541–549
Lorens SA, Mitsushio H, Van de Kar LD (1989) Effects of the 5-HT1A agonist ipsapirone on the behavioral, endocrine and neurochemical responses to conditioned fear. In: Bevan P, Cools AR, Archer T (eds) Behavioural Pharmacology of 5-HT. Lawrence Erlbaum, Hillsdale, pp 367–369
Matheson GK, Gage-White D, White G, Guthrie D, Rhoades J, Dixon V (1989) The effects of gepirone and 1-(2-pyrimidinyl)-piperazine on levels of corticosterone in rat plasma. Neuropharmacol 28: 329–334
Nieuwenhuys R (1985) Chemoarchitecture of the brain. Springer, Berlin Heidelberg New York
Owen RT, Tyrer P (1983) Benzodiazepine dependence. A review of evidence. Drugs 25: 385–398
Scrip (1988) Scrip's serotonin report. An overview of drugs in development that act on serotonin. PJB, Richmond Surrey, UK
Sprouse J, Aghajanian GK (1987) Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1: 3–9
Traber J, Davies MA, Dompert WU, Glaser T, Schuurman T, Seidel P-R (1984) Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821. Brain Res Bull 12: 741–744
Traber J, Glaser T (1987) 5-HT1A receptor-related anxiolytics. Trends Pharmacol Sci 8: 432–437
Tuomisto J, Mannisto P (1985) Neurotransmitter regulation of pituitary hormones. Pharmacol Rev 37: 250–332
Van de Kar LD (1989) Neuroendocrine aspects of the serotonergic hypothesis of depression. Neurosci Biobeh Rev 13: 237–246
Ward DG, Bolton MG, Gann DS (1978) Inhibitory and facilitatory areas of the ventral midbrain mediating release of corticotropin in the cat. Endocrinol 102: 1147–1156
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beneke, M., Wingender, W., Horstmann, R. et al. Neuroendocrine effects of ipsapirone on the hypothalamic-pituitary adrenal axis: CRF, ACTH and cortisol in healthy volunteers. Eur J Clin Pharmacol 42, 163–169 (1992). https://doi.org/10.1007/BF00278478
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278478